Effect of Metformin on systemic chemokine responses during anti-tuberculosis chemotherapy.
Tuberculosis (Edinb)
; 148: 102523, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38850838
ABSTRACT
BACKGROUND:
Metformin (MET), by boosting immunity, has been suggested as a host-adjunctive therapy to anti-tuberculosis treatment (ATT).METHODS:
We evaluated whether adding MET to the standard ATT can alter the host chemokine response. We investigated the influence of metformin on the plasma levels of a wide panel of chemokines in a group of active tuberculosis patients before treatment, at 2nd month of ATT and at 6-months of ATT as part of our clinical study to examine the effect of metformin on ATT.RESULTS:
Our results demonstrated that addition of metformin resulted in diminished CC (CCL1 and CCL3) and CXC (CXCL-2 and CXCL-10) chemokines in MET arm as compared to non-MET arm at the 2nd month and 6th month of ATT. In addition to this, MET arm showed significantly diminished chemokines in individuals with high bacterial burden and cavitary disease.CONCLUSION:
Our current data suggest that metformin alters chemokines responses that could potentially curb excessive inflammation during ATT.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quimiocina CXCL10
/
Metformina
/
Antituberculosos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article